ArticleInternational journal of molecular medicine2018
Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg.
Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 18 citations in OpenAlex.
- Mutational landscape of the surface antigen of hepatitis B virus in patients with hepatocellular carcinoma.Gut pathogens · 2025Article
- [Expert consensus on the clinical application of the markers of hepatitis B virus].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Article
- Research Progress on the Mechanism of Persistent Low-Level HBsAg Expression in the Serum of Patients with Chronic HBV Infection.Journal of immunology research · 2022Review
- Analysis of S gene characteristic sequences and changes in properties of protein expression in HBV ASCs with low-level HBsAg.Frontiers in medicine · 2022Article
- Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.Viruses · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a hepatitis B virus (HBV)‑infected population, persistently low expression levels of serum HBV serum antigen (HBsAg) are present, particularly in chronic asymptomatic HBV carriers (ASCs). The present study sequenced the HBV Pre‑S gene, and aimed to elucidate its features in ASCs with low HBsAg expression compared with in the established HBV Pre‑S reference gene sequences from ASCs with high HBsAg expression. A total of 1,308 ASCs were grouped according to HBsAg serum levels (cut‑off value, 10 IU/ml), and clinical characteristics were analyzed in detail. The HBV Pre‑S gene was sequenced in 276 ASCs with low‑level HBsAg; in addition, 100 of the remaining 1,032 ASCs with high‑level HBsAg were randomly selected for HBV Pre‑S gene sequencing on the basis of age matching with the low‑level HBsAg group. Comparative analysis of the gene sequences from these groups was subsequently conducted. The major clinical features of the population with low‑level HBsAg were as follows: Most were ASCs with chronic HBV infection; 97.1% were HBsAg/anti‑HBe/anti‑HBc‑positive; 82.54% carried the B genotype; and 84.13% displayed the adw serotype. The results indicated that there were novel and meaningful mutations, including co‑mutations, at numerous loci and sites in the Pre‑S gene, as well as deletion mutations in the Pre‑S2 gene. These mutations in the Pre‑S1 and Pre‑S2 gene fragments accounted for 65.38% (68/104) of the 104 B genotype cases in the low‑level HBsAg group and 90.91% (20/22) of the 22 C genotype cases in the low‑level HBsAg group, respectively. In conclusion, Pre‑S gene mutations may be associated with HBV replication defects, which may be the cause of the observed low expression levels of HBsAg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.